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Background: NKX2-1mutations have been described in several patients with primary congenital hypothyroidism,
respiratory distress, and benign hereditary chorea, which are classical manifestations of the brain–thyroid–lung
syndrome (BTLS).
Methods: The NKX2-1 gene was sequenced in the members of a Brazilian family with clinical features of BTLS,
and a novel monoallelic mutation was identified in the affected patients. We introduced the mutation in an
expression vector for the functional characterization by transfection experiments using both thyroidal and
lung-specific promoters.
Results: The mutation is a deletion of a cytosine at position 834 (ref. sequence NM_003317) (c.493delC) that
causes a frameshift with formation of an abnormal protein from amino acid 165 and a premature stop at
position 196. The last amino acid of the nuclear localization signal, the whole homeodomain, and the carboxy-
terminus of NKX2-1 are all missing in the mutant protein, which has a premature stop codon at position 196
(p.Arg165Glyfs*32). The p.Arg165Glyfs*32 mutant does not bind DNA, and it is unable to transactivate the
thyroglobulin (Tg) and the surfactant protein-C (SP-C) promoters. Interestingly, a dose-dependent dominant
negative effect of the p.Arg165Glyfs*32 was demonstrated only on the Tg promoter, but not on the SP-C
promoter. This effect was also noticed when the mutation was tested in presence of PAX8 or cofactors that
synergize with NKX2-1 (P300 and TAZ). The functional effect was also compared with the data present in the
literature and demonstrated that, so far, it is very difficult to establish a specific correlation among NKX2-1
mutations, their functional consequence, and the clinical phenotype of affected patients, thus suggesting that
the detailed mechanisms of transcriptional regulation still remain unclear.
Conclusions: We describe a novel NKX2-1 mutation and demonstrate that haploinsufficiency may not be the
only explanation for BTLS. Our results indicate that NKX2-1 activity is also finely regulated in a tissue-specific
manner, and additional studies are required to better understand the complexities of genotype–phenotype
correlations in the NKX2-1 deficiency syndrome.
Introduction
NK2 homeobox 1 (NKX2-1, also called TTF-1; MIM#600635) was initially identified in rat thyroid cells as a
42 kDa phosphorylated nuclear protein able to bind to the
thyroglobulin (Tg) promoter (1). It belongs to the NKX2
class of transcription factors and is encoded by a three-
exon structured gene located on chromosome 14q13. Dur-
ing human development, the gene is expressed in the
ventral diencephalon, telencephalon, lung bud, and the
thyroid primordium (2,3). Nkx2-1 null mice lack thyroid
and pituitary glands, have lung hypoplasia with se-
vere respiratory failure, and have defects in the ventral
forebrain (4).
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The association of choreoathetosis, hypothyroidism, and
pulmonary alterations was linked to mutations in the gene
encoding NKX2-1 in the so-called brain–thyroid–lung syn-
drome (BTLS).
A novel NKX2-1 mutation was identified and function-
ally characterized in a family with five affected patients in
two generations showing hypothyroidism, benign heredi-
tary chorea, and respiratory distress. All the affected
members presented a heterozygous deletion of the cytosine
at position 834 (ref. sequence NM_003317) of the NKX2-1
gene (c.493delC). The mutation is responsible for a frame-
shift that produces an abnormal protein from amino acid
165 with a premature stop codon at position 196.
Materials and Methods
Patients
The family included five affected patients in two genera-
tions living in Curitiba, Brazil (Fig. 1). All family members
gave their informed consent for the study. The study was
approved by the ethical committee of each participating in-
stitution. The clinical characteristics of the affected members
of the family are reported in the Results section.
DNA amplification and sequencing
Genomic DNA was extracted from peripheral blood
leukocytes of all family members. The three exons of the
NKX2-1 gene were amplified by polymerase chain reaction
(PCR) as previously described (5). PCR products were pu-
rified with Antarctic phosphatase-exonuclease I (New
England BioLabs, Ipswich, MA) at 37!C for 15 minutes and
80!C for 15 minutes for the enzyme activation and inacti-
vation respectively and the products were bidirectionally
sequenced with a 377 ABI sequencer (Applied Biosystems,
Foster City, CA). The genes encoding PAX8 (6), NKX2.5 (7),
and TAZ (8) were also amplified and sequenced as previously
described. To exclude the presence of polymorphysms, 100
normal subjects were also screened as controls.
Mutagenesis
The mouse Nkx2-1 gene from the p3XFLAG-CMV-10-
NKX2-1 vector was used as template in a PCR with the sense
primer 5¢-CCGCCGGAAGCGCGGGTGCTC TTC T-3¢ and
the antisense primer 5¢-GAGAAGAGCACC CGCGCT TCC
GGC-3¢ using the QuikChange Site-Directed Mutagenesis kit
(Agilent Technologies, La Jolla, CA) according to the manu-
facturer’s procedure. The presence of the mutation in the
obtained vector was confirmed by direct sequencing.
Western blot
HEK293 cells were transiently transfected with 10 lg of
either wild-type (WT)-Nkx2-1 or c.493delC-Nkx2-1 plasmids
using the FuGene 6 Transfection Reagent (Roche, Indiana-
polis, IN) according to the manufacturer’s instructions. After
48 hours, cells were scraped in phosphate-buffered saline (pH
7.4) and centrifuged at 1792 g for 5 minutes at 4!C. Pellets
were frozen and stored at -80!C until used to prepare nuclear
or total extracts as previously described (5).
Tenmicrograms and 40 lg each of nuclear and total extracts
were boiled in Laemmli buffer and resolved on a 12% SDS-
PAGE gel. The gel was blotted on Immobilon P (Millipore
Corp., Bedford, MA) for 90 minutes at a constant current of
100 mA. Immunodetection of NKX2-1 was performed by
using a monoclonal anti-FLAG antibody (M2; Sigma, St.
Louis, MO) diluted 1:3000 in Tris-buffered saline containing
5% nonfat milk (Bio-Rad Laboratories, Inc., Richmond, CA),
and the filter was treated with a 1:3000 dilution of goat anti-
mouse IgG conjugated to horse radish peroxidase (Bio-Rad).
Electrophoretic mobility shift assay
The binding to DNA of the c.493delC mutant was studied
by electrophoretic mobility shift assay (EMSA) using double-
stranded end-labeled oligonucleotide C for the Tg promoter
as described (9), and double-stranded end-labeled oligonu-
cleotide C2 for the surfactant protein C (SP-C) promoter (10).
Cell culture and in vitro functional assays
HEK293 and HeLa cells were maintained in Dulbecco’s mod-
ified Eagle’s medium supplemented with 2mM L-glutamine,
4.5g/L D-glucose, 50U/mL penicillin, 50lg/mL streptomycin,
and 10% fetal bovine serum under humidified 5% carbon
dioxide/95% air at 37!C and grown in 24-well plates to
70%–80% confluence (i.e.,*5 · 104 cells per well).
HeLa cells were transfected with the reporter plasmid
(0.1 lg of pTg-Luc, 0.3 lg of SP-C-Luc 0.32) plus 3 ng of
CMV-Ren as an internal control vector, and different doses
of effector plasmids. HEK293 cells were transfected with
0.1 lg of the reporter pTg-Luc plasmid and 1.5 ng of CMV-
Ren internal control vector plus different doses of effector
plasmids. In each set of transfection experiments, the total
amount of transfected DNAwas normalized using an empty
vector.
Transfections were performed with the TurboFect in vitro
Transfection Reagent (Fermentas Life Sciences, Pittsburgh,
PA), using a DNA/Turbofect ratio of 1:2 in all experiments.
Cells were harvested after 36–48 hours and analyzed se-
quentially for firefly and Renilla luciferase activities (Dual-
Luciferase Reporter Assay System, Promega, Madison, WI).
FIG. 1. Pedigree of the
studied family. The family
members carrying the
c.493delC mutation
(p.Arg165Glyfs*32) and
showing the clinical manifes-
tation of brain–thyroid–lung
syndrome (BTLS) are in black.
The proband (III-6) is indi-
cated by an arrow.
676 NETTORE ET AL.
The ratios between the measured firefly and Renilla lucifer-
ase activities were expressed relative to the ratios obtained in
cells transfected with the reporter and an empty expression
vector (CMV-Flag) only. Transfection experiments were
performed in duplicate and repeated at least three times.
Data are shown as mean – SD. Statistical analysis was per-
formed using Student’s t-test.
Results
Patients
The family included five affected patients in three gen-
erations (Fig. 1). Collection of clinical information was dif-
ficult because the members of the family live in different
towns; therefore, some of the clinical characteristics were
missing.
The proband (III-6) was the fifth child of nonconsanguine-
ous parents. Hewas born at termwith a birth weight of 2820g,
but a delay in motor development was soon evident: he took
his first steps at 24months of age. During infancy, the proband
showed moderate generalized choreiform movements and
cerebellar ataxia that remained stable thereafter, accompanied
by several episodes of respiratory insufficiency that were di-
agnosed either as asthma or pneumonia. Routine blood
chemistry and hematology tests and electrocardiograms were
normal. Brain MRI, electromyography, and muscle biopsy
were also normal.
When the proband was 13 years old, his thyroid function
tests (TFTs) revealed subclinical hypothyroidism: serum
thyrotropin (TSH) was 9.1mU/L (normal range 0.35–
4.94mU/L), free thyroxine (FT4) was 1.07 ng/dL (normal
range 0.7–1.48 ng/dL) and triiodothyronine (T3) was
127.55 ng/dL (normal range 58–159 ng/dL). Serum anti-
thyroid antibodies tests were negative.
The proband’s mother (II-1) presented with short stature,
mild generalized choreiform movements since infancy, sub-
clinical hypothyroidism (TSH 8.51mU/L, FT4 1.07 ng/dL, T3
109.46 ng/dL), and episodes of respiratory insufficiency (di-
agnosed as asthma) in childhood.
Subject III-2, a brother of the proband, presented with
cervical dystonia, moderate generalized choreiform move-
ments, and hypothyroidism (TFT not available) at the age of
22 years.
Subject III-4 (the oldest sister of the proband) was diag-
nosed with a mild choreiform movement disorder at the age
of 17 years. At that time, subclinical hypothyroidism (TSH
8.13mU/L, FT4 1.1 ng/dL, T3 122.08 ng/dL) was also noticed.
She was treated with 25 lg/d of L-thyroxine, which normal-
ized serum TSH levels.
The proband’s youngest sister (III-5) presented with mod-
erate generalized choreiform movements, mild cognitive
deficit, and subclinical hypothyroidism (TSH 5.43mU/L, FT4
1.19 ng/dL, T3 126.60 ng/dL) at the age of 14 years.
All the other members in the family (I-1, I-2, II-2, II-3, III-1,
III-3, III-7, III-8, III-9) had normal TFTs and normal thyroid
morphology on ultrasound examination.
Sequencing
Sequencing of the NKX2-1 coding region of the proband’s
DNA revealed a new monoallelic deletion of the cytosine at
position 834 (accession no. NM_003317.3). The mutation is
responsible for a frameshift that produces an abnormal pro-
tein from amino acid 165. The last amino acid of the nuclear
localization signal (NLS), the whole homeodomain, and the
carboxy-terminus of NKX2-1 are all missing in the mutant
protein, which has a premature stop codon at position 196
(p.Arg165Glyfs*32). The mutant protein has an approximate
molecular weight of 20 kDa.
The same mutation (TRANSNP_1331899076), never de-
scribed before, was present in all the affected members of the
family but not in any of the unaffected members of the family
or in the 100 normal controls.
No mutations were detected in the coding sequences of
PAX8, NKX2-5, and TAZ genes in the family members or in
the 100 normal controls.
Nuclear localization
Since the c.493delC mutation occurs in the codon encoding
for the last amino acid of the NLS of NKX2-1, we tested the
effect on the nuclear localization. To this aim, HeLa cells were
transfected with either the WT-Nkx2-1 or the c.493delC-Nkx2-
1. After 24 hours, both nuclear and cytoplasmatic proteins
were extracted from transfected cells andWestern blot results
are shown in Figure 2.
As expected, WT-NKX2-1 was synthesized and migrated
into the nucleus, disappearing from the cytosolic extracts.
Despite the alteration of the nuclear localization signal, the
c.493delC was able to migrate into the nucleus.
These results indicate that the p.Arg165Glyfs*32 was syn-
thesized and was capable of migrating into the nucleus.
DNA binding capacity
DNA binding properties of the c.493delC mutant were also
analyzed by EMSA using a short DNA stretch corresponding
to the NKX2-1 binding site within the Tg promoter (oligo C)
(9) and the SP-C promoter (oligo C2) (10). The results are
shown in Figure 3. A retarded band could be detectedwith the
WT, while the c.493delC NKX2-1 was, as expected, unable to
bind to DNA because of the absence of the homeodomain.
Moreover, the addition of the same or double amount of
c.493delC extracts did not reduce the binding of WT-NKX2-1.
This indicates that c.493delC-NKX2-1 was unable to physi-
cally interact andmodulateWT-NKX2-1 binding toDNA. The
specificity of all the observed complexes was demonstrated in
competition experiments adding a 100-fold excess of cold
oligos.
FIG. 2. Western blot analysis with the anti-FLAG anti-
bodies of cytosolic and nuclear extract of the cells transfected
with both wild-type (WT) and c.493delC (p.Arg165Glyfs*32)
cloned into the p3XFLAG-CMV-10 plasmid. The c.493delC is
normally synthesized and able to migrate into the nucleus.
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Transactivation capacity of mutated
and WT NKX2-1 proteins
The transcriptional properties of both WT- and c.493delC-
NKX2-1 were investigated by co-transfection assays as pre-
viously described. As expected, the c.493delC mutant was
unable to activate both the Tg (11) and the SP-C promoters
(12).
Thereafter co-transfection experiments were performed
using both WT and the c.493delC mutant on the same pro-
moters. Interestingly we were able to demonstrate a dose-
dependent dominant negative effect of the c.493delC mutant
on the WT-NKX2-1 when used with the Tg promoter (Fig.
4A), but no dominant negative effect could be demonstrated
on the SP-C promoter (Fig. 4B), indicating that the c.493delC
mutant produced a dominant-negative effect on thewild-type
NKX2-1 in a promoter-specific manner.
To further understand the dominant-negative action and
investigate the c.493delC effects, co-transfection experi-
ments were performed with PAX8, P300, and TAZ on the
Tg promoter.
PAX8 (Paired Box Gene 8) is a transcription factor ex-
pressed in the thyroid but not in the lung. It synergizes with
NKX2-1 to stimulate Tg and thyroperoxidase promoter ac-
tivities (13).
P300 (E1A-Binding Protein), a general transcriptional
coactivator, plays a pivotal role in the activity of many tran-
scription factors, either by bridging sequence-specific DNA-
binding factors with elements of the basal transcriptional
machinery, such as transcription factor IIB and polymerase 2,
or by its intrinsic histone acetyltransferase activity. NKX2-1,
PAX8, and P300 physically interact with each other (13–15),
and the functional synergism may involve the direct cooper-
ation of all three factors. The addition of P300 increases the
transactivation properties of PAX8, NKX2-1, and both factors
together.
TAZ (transcriptional co-activator with a PDZ-binding
motif, also known asWWTR1) is also present in thyroid tissue
and in differentiated thyroid cell lines (16), thus acting as a
potent co-activator for both PAX8 (16) and NKX2-1 (17).
As previously shown (13), we were able to demonstrate
that PAX8 synergized with the WT protein and increased Tg
promoter activity. The co-transfection with the c.493delC did
not modify the PAX8 basal activity, and the dominant nega-
tive effect was also present when both WT and c.493delC
proteins were transfected with PAX8 (Fig. 5).
FIG. 3. DNA binding capability of the c.493delC mutant
(p.Arg165Glyfs*32). Electrophoretic mobility shift assay
(EMSA) was performed with nuclear extracts of HEK293
cells transfected with WT and c.493delC constructs on the
thyroglobulin (Tg) promoter (A) and surfactant protein C
(SP-C) promoter (B). Arrowheads indicate the bound NKX2-
1 to the oligos. The co-transfection of the WT-Nkx2-1with the
same (+/+) or double (+/+ +) amount of the mutant
c.493delC does not reduce the binding of the WT. Extracts
were also incubated with a large excess (100-fold) of cold
oligos as a competitor that produced a significant displace-
ment of the bound labeled probe.
FIG. 4. Transcriptional activation of Tg and the SP-C pro-
moters. (A) Effects of transfection of WT-NKX2-1 and
c.493delC-NKX2-1 on the Tg promoter. Addition of increas-
ing amounts (12.5, 25, 50 ng) of c.493delC to a constant
amount (50 ng) of the WT produced a significant decrease in
the promoter activity (***p< 0.001). (B) Effects of transfection
of WT-Nkx2-1 and c.493delC-Nkx2-1 on the SP-C promoter.
Contrary to what was observed for Tg, addition of increasing
amounts (12.5, 25, 50 ng) of c.493delC to a constant amount
(50 ng) of the WT did not reveal a dominant negative effect.
FIG. 5. Synergism with PAX8. Transcription activation of
the Tg promoter by WT-NKX2-1 and c.493delC-NKX2-1 in
the interaction with PAX8. HeLa cells have been transfected
with 50 ng of each plasmid and 100 ng of the reporter. The
addition of WT produced a significant (***p< 0.001) increase
in the PAX8 activity, while the addition of the c.493delC had
no effect. If both WT-Nkx2-1 and c.493delC-Nkx2-1 were
transfected, the dominant negative effect of the mutant on
the WT protein was still present. The presence of PAX8 did
not rescue the dominant negative effect on the Tg promoter.
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To further study the interplay of P300, PAX8, and both WT
and c.493delC proteins, co-transfection experiments were
performed in HEK293 cells, since these cells lack the endo-
genous P300 (18). Again, if the c.493delC was added to the
cells, there was no increase in the activation produced by
PAX8 and/or P300, suggesting that this truncated protein did
not interfere with the complex. Finally, when all four factors
were present (WT, c.493delC, PAX8 and P300), a slight de-
crease in the activity could be observed compared with the
multiprotein complex of NKX2-1/PAX8/P300 (Fig. 6).
These results indicate that the dominant negative effect can
also be observed when a multifactorial complex is present,
and PAX8 or P300 are unable to rescue the effect of the
mutation.
Similar results were obtained when the coactivator TAZ
was used in HeLa cells (data not shown).
Discussion
Mutations in NKX2-1 have been demonstrated to be re-
sponsible for several cases of BTLS, and in this article we
describe a novel mutation in the gene encoding for NKX2-1 in
a family with the clinical manifestations of benign hereditary
chorea, hypothyroidism, and respiratory distress. The muta-
tion c.493delC results in a protein of 196 amino acids. The
mutant protein contains a frameshift and differs from the WT
beginning at position 165, which corresponds to the last
amino acid of the NLS. Transfection experiments with the
mutant protein demonstrate that the c.493delC protein is
synthesized and translocates into the nucleus, but it is unable
to bind DNA since it completely lacks the homeodomain. The
c.493delC mutant was responsible for a clear dose-dependent
dominant negative effect on the WT NKX2-1 when tested on
the Tg promoter, whereas when functional assays were per-
formed on the lung SP-C promoter, the c.493delC mutant
showed no dominant negative effect.
Several mutations inNKX2-1 have been reported (5,19–38),
and in the majority of cases haploinsufficiency has been con-
sidered to be responsible for the phenotype, as also sug-
gested by the finding of motor abnormalities and mild
hyperthyrotropinemia in the Nkx2-1 heterozygous knockout
mice (19). Only a fewmutations (Table 1) produce a dominant
negative effect on the WT NKX2-1 (20,21), and there is only
one case among them describing a promoter-specific domi-
nant negative effect (22). In this last case, contrary towhat was
observed for the c.493delC, the mutant protein contained the
homeodomain and could bind to DNA. The authors sug-
gested that the possible interference of the mutant NKX2-1
(p.P275fs*74) with the cooperative interaction between
NKX2-1 and PAX8 or NKX2-1 and other cofactors on the Tg
promoter is the cause of the promoter-specific dominant
negative effect. Since our mutant did not bind to DNA, it is
probable that the amino terminus of NKX2-1 binds to other
factors that are relevant for its activity on the Tg promoter,
thus excluding them from the transcriptional complex and
reducing the activity of theWTNKX2-1. In fact, tissue-specific
transcriptional regulation is achieved by the combined inter-
action among transcription factors, co-regulators, and other
components regulating basal transcription. In the thyroid,
NKX2-1 physically interacts with both PAX8 (13) and TAZ
(16). In addition P300, a ubiquitous transcriptional cofactor,
has been demonstrated to play an important role for the
NKX2-1/PAX8 synergy (14,39). PAX8, P300, and TAZ were
tested to see whether they could influence the transactivation
of NKX2-1 on its target promoters. The presence of these co-
factors increased the activation of the Tg and SP-C promoters,
but did not change the thyroid-specific dominant negative
effect. In addition, no rescue of the NKX2-1/PAX8 synergism
was observed, contrary to what was previously reported in
the case of a PAX8 mutation (39).
It has been suggested that NKX2-1 binds to DNA as a dimer
(40) and that the interaction with PAX8 occurs via the amino
terminus of theNKX2-1 protein (13). Several other factors,most
of which not yet defined, may be involved in the regulation of
transcription. We believe that the truncated NKX2-1 mutant
described in this article interferes with the activity of WT-
NKX2-1, decreasing the activity of the multiprotein transcrip-
tional complex. It is likely that PAX8 plays a critical role in
modulating this effect in thyroid cells. In lung cells, where
PAX8 is absent, the dominant negative effect can not be ob-
served. Even if HeLa cells do not express PAX8, it has been
previously suggested that other proteins with a similar activity
may replace the function of PAX8 on the Tg promoter (22).
Very recently Silberschmidt and coworkers (41) produced
mice lacking one of the two redundant activation domains of
Nkx2-1, or having defective phosphorylation of the protein.
They demonstrated that each mutant shows a distinct phe-
notype. They also revealed a level of complexity that could
not be predicted by experiments carried out in cultured cells
and stressed the discrepancy between the results in the cell
models and in those that can be obtained in whole organisms
(41). In this context, themajormolecular effect of ourmutation
on the Tg promoter is dominant, while hypothyroidism is
only mild (subclinical) in all the affected members of our
FIG. 6. Effect of P300. HEK293 cells were co-transfected
with WT-Nkx2-1 (50 ng), c.493delC-Nkx2-1 (50 ng), PAX8
(50 ng), and P300 (300 ng) expression vectors, and the pTg-
Luc reporter (100 ng) in the indicated combinations. The
addition of P300 significantly increased the activity of the Tg
promoter in response to WT-NKX2-1 and PAX8, but had no
effects on the activity of c.493delC. The cooperation between
WT, PAX8, and P300 produced an additional increase in the
activity, while the activation of the complex c.493delC/PAX8
did not differ from the activation observed when PAX8 was
co-transfected with P300 alone. Finally, when all the factors
were present, there was a reduction of the activation com-
pared with the WT +PAX8 complex, as a consequence of the
dominant negative effect of the c.493delC mutant on the WT.
Significant differences between the samples with and with-
out P300 are indicated: ***p < 0.001.
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family. This discrepancy can be the consequence of different
mechanisms of action of the mutation in the different tissues,
but also of the complex interactions between other genetic
and/or environmental factors that may modulate the pheno-
type. All the reportedNKX2-1mutations (summarized in Table
1) have variable functional effects, even if the mutations occur
in similar regions of the protein. Indeed, the clinical features of
the affected families and family members described in the lit-
erature are very variable, and there is no correlation between
the clinical and the molecular phenotype. Mutations that pro-
duce major alterations in the protein structure may be associ-
ated with only minor neurological signs (19,26), while primary
hypothyroidism has been linked to NKX2-1 mutations in 81%
of the cases (25/31) (19,20,22,27–38).
In conclusion, a novel NKX2-1 mutation in a family pre-
senting the clinical findings of the BTLS is described. The
c.493delC mutant migrates into the nucleus but is not able to
transactivate the Tg or SP-C promoters. These results indicate
that NKX2-1 activity is finely regulated by the interaction of
several factors that are still largely unknown. The mecha-
nisms regulating gene expression are different in each tissue.
Additional studies are required to better understand the
complexities of the genotype–phenotype correlation in the
NKX2-1 deficiency syndrome.
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